Skip to main content
SpringerLink
Log in

Author’s Reply to Reith: “Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults”

  • Letter to the Editor
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

The Original Article was published on 23 June 2018

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Adapted from van Rongen et al. [2], with permission

References

  1. Reith DM, Al-Sallami HS. Comment on: Higher midazolam clearance in obese adolescents compared with morbidly obese adults. Clin Pharmacokinet. 2018. https://doi.org/10.1007/s40262-018-0691-0.

    Article  PubMed  Google Scholar 

  2. van Rongen A, Brill MJE, Vaughns JD, Valitalo PAJ, van Dongen EPA, van Ramshorst B, et al. Higher midazolam clearance in obese adolescents compared with morbidly obese adults. Clin Pharmacokinet. 2018;57(5):601–11.

    Article  PubMed  CAS  Google Scholar 

  3. Brill MJ, van Rongen A, Houwink AP, Burggraaf J, van Ramshorst B, Wiezer RJ, et al. Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers. Clin Pharmacokinet. 2014;53(12):931–41.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Liu Y, Cao W, Liu Y, Wang Y, Lang R, Yue Y. Changes in duration of action of rocuronium following decrease in hepatic blood flow during pneumoperitoneum for laparoscopic gynaecological surgery. BMC Anesthesiol. 2017;17(1):45.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Brill MJ, van Rongen A, van Dongen EP, van Ramshorst B, Hazebroek EJ, Darwich AS, et al. The pharmacokinetics of the CYP3A substrate midazolam in morbidly obese patients before and one year after bariatric surgery. Pharm Res. 2015;32(12):3927–36.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology. 1984;61(13):27–35.

    Article  PubMed  CAS  Google Scholar 

  7. Thummel KE, O’Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther. 1996;59(10):491–502.

    Article  PubMed  CAS  Google Scholar 

  8. Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, Frye RF. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther. 2002;72(8):718–28.

    Article  PubMed  CAS  Google Scholar 

  9. Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther. 1992;51(24):715–28.

    Article  PubMed  CAS  Google Scholar 

  10. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol. 1994;47(9):1643–53.

    Article  PubMed  CAS  Google Scholar 

  11. Shord SS, Chan LN, Camp JR, Vasquez EM, Jeong HY, Molokie RE, et al. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. Br J Clin Pharmacol. 2010;69(2):160–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. van Gerven JM, Roncari G, Schoemaker RC, Massarella J, Keesmaat P, Kooyman H. Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. Br J Clin Pharmacol. 1997;44(5):487–93.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Anne van Rongen was affiliated with the Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, The Netherlands, and Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy, Reinier de Graaf Hospital, Delft, The Netherlands

    Anne van Rongen

  2. Intensive Care and Department of Pediatric Surgery, Erasmus MC Sophia Children’s Hospital, Rotterdam, The Netherlands

    Johannes N. van den Anker

  3. Division of Clinical Pharmacology, Children’s National Medical Center, Washington, DC, USA

    Johannes N. van den Anker

  4. Department of Paediatric Pharmacology, University Children’s Hospital, Basel, Switzerland

    Johannes N. van den Anker

  5. Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, The Netherlands

    Catherijne A. J. Knibbe

  6. Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands

    Catherijne A. J. Knibbe

Authors
  1. Anne van Rongen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johannes N. van den Anker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Catherijne A. J. Knibbe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Catherijne A. J. Knibbe.

Ethics declarations

Funding

No sources of funding were used in the preparation of this reply.

Conflict of interest

Anne van Rongen, Johannes van den Anker, and Catherijne Knibbe declare that they have no potential conflicts of interests.

Additional information

This author’s reply refers to the letter to the editor at https://doi.org/10.1007/s40262-018-0691-0.

This reply refers to the original article available at https://doi.org/10.1007/s40262-017-0579-4.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

van Rongen, A., van den Anker, J.N. & Knibbe, C.A.J. Author’s Reply to Reith: “Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults”. Clin Pharmacokinet 57, 1357–1358 (2018). https://doi.org/10.1007/s40262-018-0692-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-018-0692-z

Search

Navigation